Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Trifluoroacetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 12/20 | 0.56 |
| ▸ | CES1 | P23141 | 9/20 | 0.54 |
| ▸ | CES2 | O00748 | 7/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.45 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Heptane SCHEMBL1776021 | 0.97 | FAAH (0.58) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL12520341 | 0.97 | FAAH (0.54) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL3273685 | 0.95 | FAAH (0.61) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL5382443 | 0.93 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL28259282 | 0.92 | FAAH (0.54) | FAAHCES1CES2MEN1CYP1A2 | |
| Nonane SCHEMBL4255344 | 0.92 | FAAH (0.62) | FAAHCES1CES2MEN1CYP1A2 | |
| Decane SCHEMBL3416451 | 0.92 | FAAH (0.62) | FAAHCES1CES2MEN1CYP1A2 | |
| Octane SCHEMBL1696265 | 0.92 | FAAH (0.62) | FAAHCES1CES2MEN1CYP1A2 | |
| Undecane SCHEMBL3628539 | 0.92 | FAAH (0.62) | FAAHCES1CES2MEN1CYP1A2 | |
| Octane SCHEMBL1123657 | 0.92 | FAAH (0.62) | FAAHCES1CES2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116500167-A | Method for separating and detecting enantiomer and diastereoisomer of baluo Sha Weizhi | 常州英诺升康生物医药科技有限公司 | 2023-07-28 | — | — | CN | claimed |
| CN-115541730-A | Method for measuring protected amino acid enantiomer | 南京锐志生物医药有限公司 | 2022-12-30 | — | — | CN | claimed |
| CN-107941970-B | Separation and detection method of D-p-hydroxyphenylglycine and enantiomer thereof | 常州合全药业有限公司 | 2021-06-08 | — | — | CN | claimed |
| CN-110041282-A | Related substance of Parecoxib Sodium and its preparation method and application | 正大天晴药业集团股份有限公司 | 2019-07-23 | — | — | CN | claimed |
| CN-109100430-A | A kind of Nateglinide chiral isomer chromatogram analysis method | 珠海同益制药有限公司 | 2018-12-28 | — | — | CN | claimed |
| CN-115029329-B | Carbonyl reductase mutant and application thereof in preparation of R-mandelic acid | 上海瀚鸿科技股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-113945672-B | Method for detecting ticagrelor and related substances thereof | 武汉武药科技有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-113336636-B | Synthesis process of DL-mandelic acid with high yield | 湖州柏特生物科技有限公司 | 2023-11-10 | — | — | CN | disclosed |
| US-20230323317-A1 | NOVEL HYDROLASE AND METHOD FOR PRODUCING (1S,2S)-1-ALKOXYCARBONYL-2-VINYLCYCLOPROPANE CARBOXYLIC ACID USING SAME | API CORPORATION (JP) | 2023-10-12 | — | — | US | disclosed |
| CN-116500167-A | Method for separating and detecting enantiomer and diastereoisomer of baluo Sha Weizhi | 常州英诺升康生物医药科技有限公司 | 2023-07-28 | — | — | CN | disclosed |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| CN-115368278-B | Method for preparing benzenesulfonic acid compound by hydrolyzing benzenesulfonamide compound | 北京鑫开元医药科技有限公司 | 2023-04-11 | — | — | CN | disclosed |
| US-5965432-A | PREFERENTIALLY METABOLIZING (S) ENANTOMORPH OF MIXTURE USING CULTURE OF ARTHROBACTER, CULTURE LIQUID, GEL IMMOBILIZED CELLS, FREEZE-DRIED OR ACETONE-DRIED CELLS, GROUND OR AUTODIGESTED CELLS, ULTRASONIC TREATED OR EXTRACTED CELLS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-10-12 | — | — | US | disclosed |
| US-5866568-A | ENDOTHELIN RECEPTOR ANTAGONIST ACTIVITY | ZENECA LIMITED (GB) | 1999-02-02 | — | — | US | disclosed |
| EP-0877736-A1 | BENZAZEPINE DERIVATIVES WITH VASOPRESSIN AGONISTIC ACTIVITY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-11-18 | — | — | EP | disclosed |
| EP-0848065-A2 | Method for improving optical purity of an amine compound | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1998-06-17 | — | — | EP | disclosed |
| EP-0832082-A1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1998-04-01 | — | — | EP | disclosed |
| WO-1997022591-A1 | BENZAZEPINE DERIVATIVES WITH VASOPRESSIN AGONISTIC ACTIVITY | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1997-06-26 | — | — | WO | disclosed |
| WO-1996040681-A1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1996-12-19 | — | — | WO | disclosed |
| US-5457225-A | Process for preparation of 5-hydroxy-3-ketoester derivative and optically active substance thereof | UBE INDUSTRIES LTD. (JP) | 1995-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | KRAS, NRAS, TP53 | FAAH 2471/4885CES1 2236/4885CES2 4107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.